Most technical analysis of Eisai Co help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Eisai from various momentum indicators to cycle indicators. When you analyze Eisai charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
It offers Aricept for the treatment of alzheimers diseasedementia with Lewy bodies Methycobal for the treatment of peripheral neuropathy and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. Eisai operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11322 people. This overview emphasizes how Eisai Co compares to peers on valuation quality and operating consistency. Current metrics include P/E of 22.87, P/B of 3.33, profit margin of 3.64%. Eisai Co has market cap of 16.17 B, P/E of 22.87, ROE of 3.5%.
Methodology
Unless otherwise specified, financial data for Eisai Co is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Eisai (USA Stocks:ESALF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Eisai Co may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Eisai Co inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Financial ratios for Eisai Co help frame valuation context across profits, cash flow, and enterprise value. They help compare Eisai across measures in a consistent way.